리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 08월
페이지 정보:영문 194 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 모노 백신 시장은 2030년까지 122억 달러에 달할 전망
2024년에 102억 달러로 추정되는 세계의 모노 백신 시장은 2024-2030년에 CAGR 3.0%로 성장하며, 2030년에는 122억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 수막염균 백신은 CAGR 3.3%를 기록하며, 분석 기간 종료시에는 52억 달러에 달할 것으로 예측됩니다. 일본뇌염 백신 분야의 성장률은 분석 기간 중 CAGR 3.6%로 추정됩니다.
미국 시장은 28억 달러, 중국은 CAGR 5.8%로 성장할 것으로 예측
미국의 모노 백신 시장은 2024년에는 28억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년 CAGR을 5.8%로, 2030년까지 24억 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 1.2%와 2.3%로 예측됩니다. 유럽에서는 독일이 CAGR 1.7%로 성장할 것으로 예측됩니다.
세계의 모노 백신 시장 - 주요 동향과 촉진요인 정리
현대의 예방접종 전략에서 모노백신이 여전히 중요한 이유는 무엇인가?
단일 병원체에 대한 예방접종을 목적으로 하는 단일 백신은 여전히 전 세계 예방접종 프로그램에 필수적인 요소입니다. 이러한 백신은 정기적인 예방접종 일정과 공중보건 캠페인에 널리 사용되고 있습니다. 특히 유아기 예방접종, 여행의학, 특정 질병 예방이 필요한 발병 대책에서 그 중요성은 분명합니다. 일반적인 예방접종으로는 홍역, B형 간염, 독감, 파상풍, 광견병 등이 있습니다.
모노백신은 면역체계를 여러 항원에 동시에 노출시키지 않고도 정확한 방어력을 제공합니다. 이는 노출 후 예방, 환자의 병력, 알레르기, 금기 사항에 따른 예방접종 등 특정 임상 상황에서 특히 중요합니다. 보건 당국은 단계적 예방접종 일정, 부스터 투여, 질병 퇴치 활동에서 표적화된 개입을 위해 백신에 계속 의존하고 있습니다.
기술이 모노백신 개발 및 생산에 어떤 영향을 미치고 있는가?
백신 개발의 기술 발전은 백신의 안전성, 안정성, 유효성을 향상시켰고, 백신 개발의 기술 발전은 백신의 안전성과 안정성을 향상시켰습니다. 최신 제조 기술로는 재조합 DNA 기술, 바이러스 유사 입자 플랫폼, mRNA 기반 개발 등이 있으며, 모두 면역 반응 개선과 부작용 감소에 기여하고 있습니다. 보조제 및 전달 시스템의 혁신도 항원 제시 및 장기 면역을 강화하고 있습니다.
콜드체인 최적화와 동결건조 제제는 저자원 환경에서 모노백신의 물류적 실행 가능성을 높이고 있습니다. 투여량 표준화, 마이크로니들 패치나 경구용 백신과 같은 무바늘 투여 방법도 개발되어 순응도 및 투여 편의성을 향상시키고 있습니다. 바이오 제조에서 세포배양 생산과 자동화의 활용이 증가함에 따라 효율적이고 비용 효율적으로 생산을 확대하는 데 도움이 되고 있습니다.
수요가 증가하고 있는 곳과 주요 최종사용자는?
소아 건강관리, 여행 의료, 공중보건, 동물용 용도에서 모노백신에 대한 수요가 증가하고 있습니다. 선진국과 개발도상국을 막론하고 국가 예방접종 프로그램에는 공중보건에 위협이 되는 질병에 대한 단일 백신이 포함되어 있습니다. 발병 지역에서는 백신이 신속하게 배치되어 질병의 확산을 억제하고 취약한 사람들을 보호할 수 있습니다.
병원, 진료소, 정부 위생국이 주요 최종사용자이며, 질병 퇴치 캠페인을 진행하는 비정부기구도 마찬가지입니다. 여행자나 의료 종사자는 지역 질병 위험에 특화된 모노 백신이 필요합니다. 수의학에서 백신은 가축과 반려동물의 개별 질병을 예방하기 위해 사용되며, 동물의 복지와 식품 안전에 기여하고 있습니다.
모노백신 시장의 성장을 가속하는 요인은 무엇인가?
백신 시장의 성장은 질병의 지속적인 확산, 표적 예방접종에 대한 규제 강화, 유연한 예방접종 옵션의 필요성 등 여러 가지 요인에 의해 주도되고 있습니다. 홍역, 간염, 광견병 등의 질병 발생은 신속한 단일 항원 예방접종에 대한 수요를 지속적으로 지원하고 있습니다. 질병에 따른 위험에 대한 인식이 높아지고 성인 예방접종 프로그램이 확대된 것도 성장에 기여하고 있습니다.
백신 설계의 기술적 진보, 보다 효율적인 제조 방법, 민관 협력은 저렴하고 효과적인 백신에 대한 폭넓은 접근을 지원하고 있습니다. 특정 감염병 퇴치에 초점을 맞춘 프로그램도 단일 백신의 보급에 크게 의존하고 있습니다. 헬스케어 시스템이 정밀한 예방접종과 노출 후 관리를 중시하는 가운데, 모노백신은 세계 백신 포트폴리오에서 확고한 위치를 유지할 것으로 예측됩니다.
부문
유형별(수막염균 백신, 일본뇌염 백신, 간염 백신, 황열 백신, 기타)
조사 대상 기업의 예
AstraZeneca Plc
Bavarian Nordic A/S
Biological E Limited
CanSino Biologics Inc.
CSL Seqirus(CSL Limited)
Daiichi Sankyo Co., Ltd.
Emergent BioSolutions Inc.
GlaxoSmithKline plc(GSK)
Merck & Co., Inc.
Moderna, Inc.
Novavax, Inc.
Panacea Biotec Ltd
Pfizer Inc.
Sanofi Pasteur(Sanofi S.A.)
Serum Institute of India Pvt. Ltd.
Sinovac Biotech Ltd.
Takeda Pharmaceutical Co., Ltd.
Valneva SE
VBI Vaccines Inc.
Zydus Lifesciences Ltd.(Zydus Cadila)
AI 통합
우리는 검증된 전문가 컨텐츠와 AI 툴로 시장 정보와 경쟁 정보를 변혁하고 있습니다.
Global Industry Analysts는 일반적인 LLM나 업계 고유 SLM에 쿼리 하는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 대량 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 큐레이트된 컨텐츠 리포지토리를 구축했습니다.
관세 영향 계수
Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Mono Vaccines Market to Reach US$12.2 Billion by 2030
The global market for Mono Vaccines estimated at US$10.2 Billion in the year 2024, is expected to reach US$12.2 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Meningococcal Vaccine, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$5.2 Billion by the end of the analysis period. Growth in the Japanese Encephalitis Vaccine segment is estimated at 3.6% CAGR over the analysis period.
The U.S. Market is Estimated at US$2.8 Billion While China is Forecast to Grow at 5.8% CAGR
The Mono Vaccines market in the U.S. is estimated at US$2.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.
Global Mono Vaccines Market - Key Trends & Drivers Summarized
Why Are Mono Vaccines Still Relevant in Modern Immunization Strategies?
Mono vaccines, which are designed to immunize against a single pathogen, remain an essential component of global vaccination programs. These vaccines are widely used in both routine immunization schedules and targeted public health campaigns. Their relevance is especially clear in early childhood immunization, travel medicine, and outbreak control where specific disease protection is required. Common mono vaccines include those for measles, hepatitis B, influenza, tetanus, and rabies.
Mono vaccines offer precise protection without exposing the immune system to multiple antigens simultaneously. This is particularly important in certain clinical situations, such as post-exposure prophylaxis or when tailoring immunization based on patient history, allergies, or contraindications. Health authorities continue to rely on mono vaccines for phased immunization schedules, booster doses, and targeted interventions in disease elimination efforts.
How Is Technology Influencing Mono Vaccine Development and Production?
Technological advancements in vaccine development have improved the safety, stability, and effectiveness of mono vaccines. Modern production techniques include recombinant DNA technology, virus-like particle platforms, and mRNA-based development, all of which contribute to improved immune response and reduced side effects. Innovations in adjuvants and delivery systems are also enhancing antigen presentation and long-term immunity.
Cold chain optimization and lyophilized formulations have increased the logistical viability of mono vaccines in low-resource settings. Standardization in dosage and needle-free delivery options, such as microneedle patches and oral vaccines, are also being developed to improve compliance and ease of administration. Increasing use of cell-culture production and automation in biomanufacturing is helping scale up production efficiently and cost-effectively.
Where Is Demand Rising and Who Are the Primary End Users?
Demand for mono vaccines is increasing in pediatric healthcare, travel medicine, public health outreach, and veterinary applications. National immunization programs across both developed and developing countries include mono vaccines for diseases that still pose public health threats. In areas where outbreaks occur, mono vaccines are rapidly deployed to control disease spread and protect vulnerable populations.
Hospitals, clinics, and government health departments are the primary end users, alongside non-governmental organizations running disease control campaigns. Travelers and healthcare workers often require mono vaccines specific to regional disease risks. In veterinary medicine, mono vaccines are used to prevent individual diseases in livestock and companion animals, supporting both animal welfare and food safety.
What Factors Are Driving Growth In The Mono Vaccines Market?
Growth in the mono vaccines market is driven by several factors including persistent disease burdens, regulatory focus on targeted immunization, and the need for flexible vaccination options. Outbreaks of diseases such as measles, hepatitis, and rabies continue to sustain demand for rapid, single-antigen immunization. Rising awareness about disease-specific risks and expansion of adult immunization programs are also contributing to growth.
Technological progress in vaccine design, more efficient production methods, and public-private collaborations are supporting broader access to affordable and effective mono vaccines. Programs focused on eliminating specific infectious diseases also depend heavily on mono vaccine deployment. As healthcare systems emphasize precision immunization and post-exposure management, mono vaccines are expected to maintain a strong position within global vaccine portfolios.
SCOPE OF STUDY:
The report analyzes the Mono Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine, Other Types)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 47 Featured) -
AstraZeneca Plc
Bavarian Nordic A/S
Biological E Limited
CanSino Biologics Inc.
CSL Seqirus (CSL Limited)
Daiichi Sankyo Co., Ltd.
Emergent BioSolutions Inc.
GlaxoSmithKline plc (GSK)
Merck & Co., Inc.
Moderna, Inc.
Novavax, Inc.
Panacea Biotec Ltd
Pfizer Inc.
Sanofi Pasteur (Sanofi S.A.)
Serum Institute of India Pvt. Ltd.
Sinovac Biotech Ltd.
Takeda Pharmaceutical Co., Ltd.
Valneva SE
VBI Vaccines Inc.
Zydus Lifesciences Ltd. (Zydus Cadila)
AI INTEGRATIONS
We're transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Mono Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Focus on Targeted Immunization Strategies Propels Demand for Mono Vaccines
Increasing Prevalence of Preventable Infectious Diseases Strengthens Use of Single-Antigen Vaccines
Expansion of National Immunization Programs Drives Procurement of Mono Vaccines for Mass Administration
Demand for Simplified Dosing and Lower Reactogenicity Supports Growth in Mono Vaccine Adoption
Global Push for Measles and Polio Eradication Sustains Long-Term Demand for Disease-Specific Vaccines
Growing Preference for Controlled Immune Response Fuels Use of Mono Vaccines in Pediatric Applications
Advancements in Antigen Isolation and Stabilization Enhance Efficacy of Mono Vaccine Formulations
Demand from Immunocompromised Patient Populations Spurs Use of Targeted Single-Disease Vaccines
Increasing R&D in Emerging Diseases Strengthens Market for Rapid-Response Mono Vaccine Platforms
Expansion of Cold Chain Infrastructure in Developing Regions Enables Wider Access to Single-Antigen Vaccines
Integration into Routine Childhood Vaccination Schedules Ensures Steady Public Sector Demand
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Mono Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Mono Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Meningococcal Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Meningococcal Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Meningococcal Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Japanese Encephalitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Japanese Encephalitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Japanese Encephalitis Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Hepatitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Hepatitis Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Hepatitis Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Yellow Fever Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Yellow Fever Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Yellow Fever Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 21: USA Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 22: USA 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 25: Canada 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
JAPAN
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 28: Japan 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
CHINA
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 30: China Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 31: China 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
EUROPE
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Mono Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 34: Europe 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 37: Europe 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
FRANCE
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: France Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 40: France 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
GERMANY
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 43: Germany 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 46: Italy 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
UNITED KINGDOM
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: UK Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 49: UK 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
SPAIN
TABLE 50: Spain Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 52: Spain 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
RUSSIA
TABLE 53: Russia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 55: Russia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 58: Rest of Europe 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Mono Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 61: Asia-Pacific 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 64: Asia-Pacific 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
AUSTRALIA
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 65: Australia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Australia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 67: Australia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
INDIA
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 68: India Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: India Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 70: India 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 71: South Korea Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: South Korea Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 73: South Korea 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Rest of Asia-Pacific Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
LATIN AMERICA
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 77: Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Mono Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 79: Latin America 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 80: Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Latin America Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 82: Latin America 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 83: Argentina Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: Argentina Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 85: Argentina 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
BRAZIL
TABLE 86: Brazil Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Brazil Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 88: Brazil 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
MEXICO
TABLE 89: Mexico Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Mexico Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 91: Mexico 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Rest of Latin America Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 94: Rest of Latin America 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
MIDDLE EAST
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 95: Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Mono Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 97: Middle East 16-Year Perspective for Mono Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 98: Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Middle East Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 100: Middle East 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
IRAN
TABLE 101: Iran Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: Iran Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 103: Iran 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
ISRAEL
TABLE 104: Israel Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: Israel Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 106: Israel 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: Saudi Arabia Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 109: Saudi Arabia 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 110: UAE Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: UAE Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 112: UAE 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Rest of Middle East Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 115: Rest of Middle East 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030
AFRICA
Mono Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 116: Africa Recent Past, Current & Future Analysis for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Africa Historic Review for Mono Vaccines by Type - Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
TABLE 118: Africa 16-Year Perspective for Mono Vaccines by Type - Percentage Breakdown of Value Sales for Meningococcal Vaccine, Japanese Encephalitis Vaccine, Hepatitis Vaccine, Yellow Fever Vaccine and Other Types for the Years 2014, 2025 & 2030